I wasn't disagreeing with you on everything you said, I was just making a comment that I believe this management has handled negotiations well previously.
I think with aryx we're all just going to have to wait and see what kind of deal they sign before judging their deal making ability. Biotechs don't usually partner when they say they will because 95% of biotech companies can't figure out underpromise overdeliver is better than hyping or giving unrealistic timelines.
Market Data 
Markets 
AI
